Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 17, 2007

CytoCore Identifies Precancerous Tissue Biomarker

  • CytoCore reported findings based on laboratory testing of the P2X7 receptor gene indicating that this biomarker is capable of distinguishing between cancerous, precancerous, and normal tissues. Data from this study also suggests that P2X7 protein and mRNA assays could potentially be developed as a screen for uterine endometrial premalignant conditions.

    "The P2X7 has demonstrated accuracy and specificity in results from our initial laboratory testing for uterine epithelial cancers, including cervical and endometrial cancers," says George Gorodeski, Ph.D., M.D., CytoCore's chief scientist and lead researcher. "Moreover, because of its widespread presence in epithelial cells throughout the body, the P2X7 could potentially differentiate precancerous conditions in other epithelial tissues not yet tested."

    CytoCore conducted a peer-reviewed medical literature search of P2X7, which the company says confirmed that it is the only marker at this time able to identify precancerous tissues before tumors develop.

    These findings have been published in Gynecologic Oncology.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »